Authors:
Wagenaar, HC
Pecorelli, S
Mangioni, C
van der Burg, MEL
Rotmensz, N
Anastasopoulou, A
Zola, P
Veenhof, CHN
Lacave, AJ
Neijt, JP
van Oosterom, AT
Einhorn, N
Vermorken, JB
Citation: Hc. Wagenaar et al., Phase II study of mitomycin-C and cisplatin in disseminated, squamous cellcarcinoma of the uterine cervix. A European Organization for Research and Treatment of Cancer (EORTC) Gynecological Cancer Group study, EUR J CANC, 37(13), 2001, pp. 1624-1628
Authors:
Neijt, JP
Engelholm, SA
Tuxen, MK
Sorensen, PG
Hansen, M
Sessa, C
de Swart, CAM
Hirsch, FR
Lund, B
van Houwelingen, HC
Citation: Jp. Neijt et al., Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer, J CL ONCOL, 18(17), 2000, pp. 3084-3092
Citation: Ea. Eisenhauer et al., Ovarian cancer: should we be managing patients with good and bad prognostic factors in the same manner?, ANN ONCOL, 10, 1999, pp. 9-15
Citation: A. Du Bois et al., First line chemotherapy with carboplatin plus paclitaxel in advanced ovarian cancer - a new standard of care?, ANN ONCOL, 10, 1999, pp. 35-41
Authors:
Berek, JS
Bertelsen, K
du Bois, A
Brady, MF
Carmichael, J
Eisenhauer, EA
Gore, M
Grenman, S
Hamilton, TC
Hansen, SW
Harper, PG
Horvath, G
Kaye, SB
Luck, HJ
Lund, B
McGuire, WP
Neijt, JP
Ozols, RF
Parmar, MKB
Piccart-Gebhart, MJ
van Rijswijk, R
Rosenberg, P
Rustin, GJS
Sessa, C
Thigpen, JT
Trope, C
Tuxen, MK
Vergote, I
Vermorken, JB
Willemse, PHB
Citation: Js. Berek et al., Advanced epithelial ovarian cancer: 1998 consensus statements, ANN ONCOL, 10, 1999, pp. 87-92